Lipid nanoparticles (LNPs) are very potent carriers for the delivery of therapeutic treatments and active pharmaceutical ingredients (APIs). Lipid nanoparticles are of great interest due to their size and biocompatibility, both of which are very important factors in determining the efficacy of APIs encapsulated in them. Currently, microfluidics has advanced to the point of offering unique tools for the production of nanoparticles in a homogeneous, controllable and reproducible way. The possibility of controlling particle size as small as 20 nm makes this technique highly versatile and offers a wide variety of applications.
Key features of the Particle Works Automated Nanoparticle System (ANP System) include running protocols with importable experiment tables to generate formulation libraries, and the ability to run in continuous mode to generate large samples once the desired formulation is optimized.
Particle Works systems have demonstrated high robustness, generating LNPs of a constant size and a polydispersity index (PDI) of < 0.2, even reaching values of 0.06. By controlling the flow ratio (FRR) between the compounds and the total flow rate (TFR), full control over the size of the nanoparticles can be achieved. This can be refined for every formulation and application, from gene therapies to vaccine development and drug delivery.
If you would like to get a first-hand look at the equipment, please visit MTB’s booth (E-33).
Translated with www.DeepL.com/Translator (free version)